GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » Treasury Stock

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Treasury Stock : $-0.33 Mil (As of Sep. 2018)


View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Medite Cancer Diagnostics's treasury stock for the quarter that ended in Sep. 2018 was $-0.33 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Medite Cancer Diagnostics Treasury Stock Historical Data

The historical data trend for Medite Cancer Diagnostics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medite Cancer Diagnostics Treasury Stock Chart

Medite Cancer Diagnostics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.33 -0.33 -0.33 -0.33

Medite Cancer Diagnostics Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.33 -0.33 -0.33 -0.33

Medite Cancer Diagnostics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Medite Cancer Diagnostics (Medite Cancer Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
4203 SouthWest 34th Street, Orlando, FL, USA, 32811
Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.
Executives
Lewis William Austin Iv director, 10 percent owner 201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles director 2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson director C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Headlines

No Headlines